Critical appraisal on the use of everolimus in renal transplantation as an immunosuppressant to prevent organ transplant rejection

Correspondence: Fernando Giron Scientific Director, Colombiana de Trasplantes, Calle 61 N 13-23 Oficina 402 Bogota, Colombia Tel +57 1 8051165 Fax +57 1 8051164 email fgiron@colombianadetrasplantes. com Abstract: Everolimus is a proliferation inhibitor designed to target chronic allograft nephropathy including prevention of acute rejection. Acute renal allograft rejection incidence varies with the therapy used for immunosuppression. Registry data show that 15% to 35% of kidney recipients will undergo treatment for at least one episode of acute rejection within the first post-transplant year. Everolimus has been used as therapy with fullor reduced-dose cyclosporine A without evidence of increasing the acute rejection incidence. This review will summarize the available clinical trial data on the use of everolimus and its role in preventing acute rejection incidence in renal transplantation.